Sarepta Therapeutics, Inc. (SRPT): Price and Financial Metrics
SRPT Stock Summary
- Price to trailing twelve month operating cash flow for SRPT is currently 53.33, higher than 90.98% of US stocks with positive operating cash flow.
- Of note is the ratio of Sarepta Therapeutics Inc's sales and general administrative expense to its total operating expenses; only 16.25% of US stocks have a lower such ratio.
- Revenue growth over the past 12 months for Sarepta Therapeutics Inc comes in at 41.82%, a number that bests 87.98% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Sarepta Therapeutics Inc, a group of peers worth examining would be EDIT, STRO, ALPN, XLRN, and SRRK.
- Visit SRPT's SEC page to see the company's official filings. To visit the company's web site, go to www.sarepta.com.
SRPT Stock Price Chart Interactive Chart >
SRPT Price/Volume Stats
|Current price||$71.14||52-week high||$181.83|
|Prev. close||$72.16||52-week low||$68.04|
|Day high||$73.34||Avg. volume||1,908,583|
|50-day MA||$80.39||Dividend yield||N/A|
|200-day MA||$126.32||Market Cap||5.65B|
Sarepta Therapeutics, Inc. (SRPT) Company Bio
Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The company was founded in 1980 and is based in Cambridge, Massachusetts.
SRPT Latest News Stream
|Loading, please wait...|
SRPT Latest Social Stream
View Full SRPT Social Stream
Latest SRPT News From Around the Web
Below are the latest news stories about Sarepta Therapeutics Inc that investors may wish to consider to help them evaluate SRPT as an investment opportunity.
RBC Capital Stick to Their Buy Rating for Sarepta Therapeutics
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 887 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
A potentially misinterpreted clinical trial readout from January may mean a market opportunity for bargain hunters.
The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 18) AngioDynamics, Inc. (NASDAQ: ANGO ) Anixa Biosciences, Inc. (NASDAQ: ANIX ) ENDRA Life Sciences Inc. (NASDAQ: NDRA ) (announced a collaboration with Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA ) for NASH studies) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Neos Therapeutics, Inc. (NASDAQ: NEOS ) (reacted to the shareholder meeting held to vote on the proposal to merge with Aytu BioScience, Inc. (NASDAQ: AYTU )) NuVasive, Inc. (NASDAQ: NUVA ) SI-BONE, Inc. (NASDAQ: SIBN ) Sierra Oncology, Inc. (NASDAQ: SRRA ) Silverback Therapeutics, Inc. (NASDAQ: SBTX ) Terns Pharmaceuticals, Inc. (NASDAQ: TERN ) Varian Medical Systems, Inc. (NASDAQ: VAR ) Veric...
Needham Stick to Their Buy Rating for Sarepta Therapeutics
SRPT Price Returns
Continue Researching SRPTWant to see what other sources are saying about Sarepta Therapeutics Inc's financials and stock price? Try the links below:
Sarepta Therapeutics Inc (SRPT) Stock Price | Nasdaq
Sarepta Therapeutics Inc (SRPT) Stock Quote, History and News - Yahoo Finance
Sarepta Therapeutics Inc (SRPT) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!